A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Open Access
- 9 September 2024
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-10
Abstract
This single-arm phase II non-randomised trial (ACTRN12619001265167) evaluated trastuzumab emtansine in solid cancers with HER2 amplification or mutation detected by comprehensive genomic profiling. The primary objective was objective response (OR), while secondary objectives included the time to progression (TTP) on study to TTP on prior therapy ratio, progression-free survival (PFS) and overall survival (OS). The cohort included 16 tumours with HER2 mutations (group 1) and 16 with HER2 amplification (group 2). After 17 months median follow-up, ORs occurred in 19% of group 1 (1 salivary gland carcinoma (SGC), 2 lung cancers) and 25% of group 2 (3 SGCs, 1 uterine carcinoma). Fourteen of 29 TTP-evaluable patients achieved a TTP ratio ≥1.3, including 10 without an OR. Median PFS and OS were 4.5 (95% CI 2.1–7.0) and 18.2 months (95% CI 8.1-not reached) respectively. Trastuzumab emtansine showed modest ORs and a favourable change in disease trajectory in select HER2-altered solid cancers.Keywords
Funding Information
- Australian Institute of Health and Welfare, Australian Government
This publication has 42 references indexed in Scilit:
- HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung CancersJournal of Thoracic Oncology, 2016
- HER2-positive breast cancer: a new piece of the puzzleThe Lancet Oncology, 2014
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinomaAnnals of Oncology, 1996
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neckCancer, 1988
- Charts for the early stopping of pilot studies.Journal of Clinical Oncology, 1984